News & Updates

Compared with aspirin alone, treatment with a P2Y₁₂ inhibitor (clopidogrel or ticagrelor) is associated with lower risks of cardiovascular (CV) death, myocardial infarction (MI), or stroke in patients with established coronary artery disease (CAD), according to the PANTHER* trial presented at ESC 2022.

Despite the decline in its use over the years, digoxin toxicity continues to be a pertinent public health matter, with mortality rates exceeding 10 percent, a recent study has found. Meanwhile, treatment with digoxin immune fab (DIF) appears to have limited value.

Among people who suffer a coronary event, return to work (RTW) is hindered by occupational physical constraints, a recent study has found.